All News
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Dot the "i", Cross the "t" (10.11.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.
Read Article
Stop Counting Bugs (10.4.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.
Read Article
I Can't Treat Ugly (9.20.2024)
Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.
Read Article
Systemic Sclerosis Insights (9.13.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Low Placental Transfer Rates with Risankizumab
There are significant concerns about the safety of drug use during pregnancy and lactation, especially newer biologic agents. This is complicated by a lack of research.
Read Article
What is the effect of cs/bDMARDs on weight in #PsA?
⬇️Weight loss seen with:
IL17i
IL23i
csDMARDs
⬆️Weight gain seen with:
TNFi
IL12/23i
Important to consider #comorbidity & #BMI in management decisions in PsA
Ab2639 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
A#2585
PsABIOnd observ cohort study of IL23 (GUS) or IL17i
6 mo interim results of 686 pts
PROs: PsAID-12
High Rx persistence at 6mo -94% on both Rx
Comparable improvement in PsAID-12 - best results skin, discomfort
1/2 with clinically meaningful improvement
#ACR24 @RheumNow https://t.co/TM1jwTRR7C
Links:
Eric Dein ericdeinmd ( View Tweet)
A#2363
Deodhar
Bimekizumab fast time to work:
BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose.
@RheumNow #ACR24 https://t.co/T81Lzyoy7m
Eric Dein ericdeinmd ( View Tweet)
A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes
Key findings:
- Significant weight loss after starting IL17i, IL23i, and csDMARDs.
- TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved
substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52.
-PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52.
Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9
Links:
Adela Castro AdelaCastro222 ( View Tweet)
BE MOBILE 1 & 2: Bimekizumab resulted in improvement of SIJ MRI inflammation & structural lesions particularly after 16 wks of treatment and continued on until wk. 52.
Supports addtl evidence of BKZ's winning streak in #axSpA
@RheumNow #ACR24 abs1757 https://t.co/EUntQIuQC8
sheila RHEUMarampa ( View Tweet)
Exciting early data for new highly selective TYK2i zasocitinib
Improved PASI skin scores (though not as much as IL23i...)
Funky skin-related adverse events at higher doses, not sure what to make of that?
#ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh
Links:
Mike Putman EBRheum ( View Tweet)
#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai
💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%)
⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai.
🔴Durable therapy ❓better outcomes
#ACR @RheumNow https://t.co/LfA3WygNVq
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Half of the respondents chose #IL17i for #psoriatic #arthritis #PsA Rx for #Achilles #tendonitis
Interesting as lots
Of data
On #enthesitis wIL23i
Likely all
Effective #PsA Rx helps #tenosynovitis
some have
➡️ data on #efficacy
⬆️ bio rationale
#ACR24 @RheumNow @ACRheum https://t.co/wzefjsfdaj
Janet Pope Janetbirdope ( View Tweet)
Summary of treatments in psoriatic arthritis #PsA @RheumNow #ACR24 https://t.co/EybzRCPLtA
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
FDA's perspective on the use of artificial intelligence in drug development.
- FDA is committed to a risk-based regulatory framework that promotes innovation & protects Pt safety
- Est. CDER AI Council to coordinate, develop, & support internal & external AI-related activities… https://t.co/BLCYmBBJMY https://t.co/fMie3oOfmn
Dr. John Cush RheumNow ( View Tweet)
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush RheumNow ( View Tweet)
Cytokines/biomarkers from IL-23/IL-17 pathways are Increased in psoriasis. Subanalysis of phase 2 254 pt PsO trial revealed that 12 wks of deucravacitinib assoc w/ reduction in IL-17A, IL-17C, beta-defensin, PI3 - decreases correlated w/ PASI changes https://t.co/Ii381B2mZx https://t.co/vXDyLUsKPi
Dr. John Cush RheumNow ( View Tweet)
UCB released topline results of a phase 3b H2H "BE BOLD" RCT of bimekizumab (anti-IL17) vs rizankizumab (anti-IL23) in 550 active adult #PsA pts - at wk 16 inhibition of IL-17A/F was superior to IL-23 using the ACR50 primary endpoint. https://t.co/aWnHYefS2C https://t.co/2Vft5fouFv
Dr. John Cush RheumNow ( View Tweet)
